| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 46 | 2026 | 290 | 15.920 |
Why?
|
| Shock, Septic | 25 | 2024 | 86 | 9.610 |
Why?
|
| Hospital Mortality | 55 | 2026 | 879 | 9.070 |
Why?
|
| Atrial Fibrillation | 40 | 2025 | 838 | 8.240 |
Why?
|
| Critical Illness | 31 | 2025 | 322 | 8.220 |
Why?
|
| Respiratory Insufficiency | 23 | 2025 | 155 | 7.980 |
Why?
|
| Respiration, Artificial | 38 | 2025 | 297 | 7.890 |
Why?
|
| Intensive Care Units | 43 | 2025 | 407 | 7.010 |
Why?
|
| Resuscitation Orders | 12 | 2022 | 49 | 4.410 |
Why?
|
| Vasoconstrictor Agents | 19 | 2025 | 70 | 4.210 |
Why?
|
| Humans | 257 | 2026 | 63586 | 3.830 |
Why?
|
| Hospitals | 18 | 2024 | 394 | 3.640 |
Why?
|
| Retrospective Studies | 81 | 2026 | 6688 | 3.450 |
Why?
|
| Hospitalization | 32 | 2025 | 1362 | 3.420 |
Why?
|
| Aged | 97 | 2026 | 14505 | 3.070 |
Why?
|
| Practice Patterns, Physicians' | 16 | 2024 | 710 | 3.010 |
Why?
|
| Pneumonia | 11 | 2024 | 291 | 2.890 |
Why?
|
| Male | 128 | 2026 | 29980 | 2.780 |
Why?
|
| Noninvasive Ventilation | 10 | 2025 | 69 | 2.720 |
Why?
|
| United States | 68 | 2024 | 7862 | 2.680 |
Why?
|
| Medicare | 13 | 2024 | 613 | 2.630 |
Why?
|
| Female | 123 | 2026 | 32991 | 2.560 |
Why?
|
| Aged, 80 and over | 52 | 2025 | 5493 | 2.480 |
Why?
|
| Erythrocyte Transfusion | 3 | 2025 | 75 | 2.440 |
Why?
|
| Critical Care | 18 | 2024 | 397 | 2.420 |
Why?
|
| Middle Aged | 87 | 2026 | 17694 | 2.360 |
Why?
|
| Risk Assessment | 22 | 2025 | 2080 | 2.230 |
Why?
|
| Stroke | 13 | 2024 | 1198 | 2.210 |
Why?
|
| Hospitals, High-Volume | 5 | 2019 | 35 | 2.090 |
Why?
|
| Patient Readmission | 9 | 2021 | 429 | 2.060 |
Why?
|
| Cohort Studies | 33 | 2025 | 2576 | 2.030 |
Why?
|
| Patient Positioning | 5 | 2025 | 49 | 2.000 |
Why?
|
| Gastrostomy | 3 | 2022 | 29 | 1.950 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 10 | 2025 | 701 | 1.910 |
Why?
|
| Biomarkers | 8 | 2024 | 1410 | 1.900 |
Why?
|
| Risk Factors | 39 | 2025 | 5363 | 1.860 |
Why?
|
| Hydrocortisone | 5 | 2024 | 193 | 1.840 |
Why?
|
| Quality Improvement | 7 | 2024 | 446 | 1.840 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2024 | 775 | 1.830 |
Why?
|
| Adult | 66 | 2025 | 16885 | 1.690 |
Why?
|
| Hypotension | 3 | 2023 | 50 | 1.680 |
Why?
|
| Organ Dysfunction Scores | 4 | 2022 | 23 | 1.670 |
Why?
|
| Norepinephrine | 7 | 2023 | 103 | 1.570 |
Why?
|
| California | 12 | 2024 | 174 | 1.550 |
Why?
|
| Quality Indicators, Health Care | 5 | 2019 | 338 | 1.540 |
Why?
|
| Positive-Pressure Respiration | 8 | 2024 | 51 | 1.520 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 435 | 1.490 |
Why?
|
| Analgesics, Opioid | 5 | 2024 | 536 | 1.470 |
Why?
|
| Pulmonary Embolism | 4 | 2018 | 174 | 1.360 |
Why?
|
| Health Services Research | 4 | 2023 | 270 | 1.360 |
Why?
|
| Life Support Care | 6 | 2018 | 20 | 1.260 |
Why?
|
| Fludrocortisone | 3 | 2024 | 4 | 1.260 |
Why?
|
| Anticoagulants | 5 | 2024 | 496 | 1.230 |
Why?
|
| Inpatients | 7 | 2022 | 305 | 1.220 |
Why?
|
| Registries | 12 | 2025 | 892 | 1.220 |
Why?
|
| Hemodynamics | 6 | 2025 | 250 | 1.210 |
Why?
|
| Terminal Care | 6 | 2024 | 110 | 1.200 |
Why?
|
| Hemoglobins | 3 | 2025 | 136 | 1.190 |
Why?
|
| Multiple Organ Failure | 4 | 2022 | 44 | 1.190 |
Why?
|
| Heart Failure | 10 | 2020 | 915 | 1.180 |
Why?
|
| Time Factors | 17 | 2025 | 3769 | 1.140 |
Why?
|
| Logistic Models | 14 | 2025 | 1277 | 1.130 |
Why?
|
| Prone Position | 8 | 2025 | 28 | 1.120 |
Why?
|
| Length of Stay | 16 | 2025 | 815 | 1.110 |
Why?
|
| Patient Discharge | 5 | 2024 | 512 | 1.110 |
Why?
|
| Tracheostomy | 6 | 2022 | 36 | 1.100 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2020 | 102 | 1.100 |
Why?
|
| Hospitals, Low-Volume | 3 | 2019 | 21 | 1.090 |
Why?
|
| Acute Lung Injury | 4 | 2020 | 45 | 1.090 |
Why?
|
| Adrenal Cortex Hormones | 8 | 2024 | 182 | 1.090 |
Why?
|
| Benchmarking | 2 | 2019 | 137 | 1.090 |
Why?
|
| Calcitonin | 2 | 2017 | 17 | 1.090 |
Why?
|
| Blood Transfusion | 2 | 2025 | 162 | 1.060 |
Why?
|
| Research Design | 6 | 2021 | 575 | 1.050 |
Why?
|
| Safety-net Providers | 2 | 2024 | 29 | 1.050 |
Why?
|
| Prognosis | 15 | 2024 | 1748 | 1.020 |
Why?
|
| Systemic Inflammatory Response Syndrome | 7 | 2022 | 44 | 0.960 |
Why?
|
| Odds Ratio | 12 | 2022 | 768 | 0.940 |
Why?
|
| Ischemic Attack, Transient | 2 | 2024 | 96 | 0.940 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2025 | 72 | 0.940 |
Why?
|
| Heart Rate | 4 | 2022 | 322 | 0.910 |
Why?
|
| Arterial Pressure | 3 | 2025 | 27 | 0.880 |
Why?
|
| Soft Tissue Infections | 2 | 2015 | 49 | 0.870 |
Why?
|
| Clinical Competence | 2 | 2020 | 729 | 0.870 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2022 | 123 | 0.860 |
Why?
|
| International Classification of Diseases | 5 | 2022 | 135 | 0.850 |
Why?
|
| Urinary Tract Infections | 2 | 2015 | 92 | 0.850 |
Why?
|
| Health Facility Closure | 1 | 2023 | 6 | 0.840 |
Why?
|
| Severity of Illness Index | 13 | 2025 | 1555 | 0.830 |
Why?
|
| Fentanyl | 1 | 2024 | 76 | 0.830 |
Why?
|
| Analgesia | 1 | 2024 | 31 | 0.820 |
Why?
|
| Central Venous Catheters | 3 | 2024 | 17 | 0.820 |
Why?
|
| Lung Diseases | 3 | 2020 | 183 | 0.820 |
Why?
|
| Risk Adjustment | 3 | 2022 | 94 | 0.810 |
Why?
|
| Anti-Bacterial Agents | 5 | 2023 | 790 | 0.790 |
Why?
|
| Adiponectin | 2 | 2014 | 36 | 0.780 |
Why?
|
| Alcoholism | 2 | 2022 | 317 | 0.760 |
Why?
|
| Pneumonia, Ventilator-Associated | 3 | 2014 | 37 | 0.740 |
Why?
|
| Vaccination | 2 | 2022 | 363 | 0.740 |
Why?
|
| Databases, Factual | 8 | 2024 | 873 | 0.720 |
Why?
|
| Leukopenia | 1 | 2021 | 15 | 0.720 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2021 | 45 | 0.710 |
Why?
|
| Tidal Volume | 7 | 2021 | 41 | 0.710 |
Why?
|
| Troponin I | 1 | 2021 | 35 | 0.710 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2024 | 172 | 0.700 |
Why?
|
| Survivors | 2 | 2023 | 177 | 0.700 |
Why?
|
| Survival Rate | 9 | 2021 | 853 | 0.700 |
Why?
|
| Cross Infection | 2 | 2014 | 164 | 0.690 |
Why?
|
| Vasodilator Agents | 3 | 2022 | 68 | 0.690 |
Why?
|
| Heart Ventricles | 3 | 2021 | 261 | 0.690 |
Why?
|
| Anemia | 1 | 2022 | 127 | 0.690 |
Why?
|
| Hypnotics and Sedatives | 4 | 2025 | 66 | 0.680 |
Why?
|
| Reward | 1 | 2021 | 87 | 0.680 |
Why?
|
| Insulins | 1 | 2021 | 15 | 0.680 |
Why?
|
| Treatment Outcome | 19 | 2024 | 5701 | 0.680 |
Why?
|
| Patient Preference | 3 | 2018 | 87 | 0.680 |
Why?
|
| Myocardial Infarction | 4 | 2019 | 919 | 0.660 |
Why?
|
| Reminder Systems | 1 | 2020 | 75 | 0.640 |
Why?
|
| Motivation | 2 | 2022 | 286 | 0.640 |
Why?
|
| Hypertension | 3 | 2022 | 588 | 0.630 |
Why?
|
| Heart Diseases | 2 | 2021 | 218 | 0.630 |
Why?
|
| Guideline Adherence | 4 | 2021 | 305 | 0.620 |
Why?
|
| Text Messaging | 1 | 2020 | 85 | 0.610 |
Why?
|
| Fruit | 1 | 2020 | 109 | 0.610 |
Why?
|
| Comparative Effectiveness Research | 2 | 2020 | 49 | 0.600 |
Why?
|
| Hospitals, Community | 1 | 2019 | 71 | 0.600 |
Why?
|
| Age Factors | 11 | 2022 | 1565 | 0.600 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 844 | 0.590 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.580 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 141 | 0.580 |
Why?
|
| Nurse-Patient Relations | 1 | 2018 | 43 | 0.570 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 54 | 0.570 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2018 | 66 | 0.570 |
Why?
|
| Nursing Staff, Hospital | 1 | 2018 | 67 | 0.560 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 108 | 0.560 |
Why?
|
| Patient Care Management | 1 | 2018 | 30 | 0.560 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 153 | 0.550 |
Why?
|
| Incidence | 12 | 2024 | 1383 | 0.550 |
Why?
|
| Massachusetts | 7 | 2025 | 2075 | 0.540 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 209 | 0.540 |
Why?
|
| Comorbidity | 10 | 2024 | 1119 | 0.540 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.530 |
Why?
|
| Cause of Death | 2 | 2019 | 221 | 0.530 |
Why?
|
| Lung Injury | 2 | 2022 | 34 | 0.530 |
Why?
|
| Epoprostenol | 2 | 2022 | 15 | 0.530 |
Why?
|
| Lung | 5 | 2024 | 956 | 0.520 |
Why?
|
| Advance Care Planning | 1 | 2017 | 65 | 0.510 |
Why?
|
| Ear Protective Devices | 1 | 2016 | 3 | 0.510 |
Why?
|
| Ventilator Weaning | 1 | 2016 | 20 | 0.500 |
Why?
|
| Quality of Health Care | 2 | 2017 | 519 | 0.500 |
Why?
|
| Health Care Surveys | 1 | 2017 | 287 | 0.500 |
Why?
|
| Bacteremia | 2 | 2015 | 94 | 0.500 |
Why?
|
| Clinical Protocols | 1 | 2017 | 134 | 0.500 |
Why?
|
| Echocardiography | 2 | 2021 | 502 | 0.480 |
Why?
|
| Delirium | 1 | 2016 | 54 | 0.480 |
Why?
|
| Clinical Coding | 1 | 2016 | 44 | 0.480 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 254 | 0.480 |
Why?
|
| Drug Overdose | 1 | 2017 | 131 | 0.480 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2015 | 20 | 0.470 |
Why?
|
| Catheterization, Central Venous | 3 | 2024 | 87 | 0.470 |
Why?
|
| Ventilators, Mechanical | 2 | 2020 | 30 | 0.470 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 95 | 0.470 |
Why?
|
| Thrombolytic Therapy | 1 | 2016 | 193 | 0.460 |
Why?
|
| Interleukin-8 | 1 | 2015 | 87 | 0.460 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 2464 | 0.460 |
Why?
|
| Acute Chest Syndrome | 2 | 2025 | 5 | 0.460 |
Why?
|
| Drug Therapy, Combination | 4 | 2024 | 467 | 0.450 |
Why?
|
| Observational Studies as Topic | 5 | 2025 | 61 | 0.450 |
Why?
|
| Decision Making | 2 | 2017 | 411 | 0.450 |
Why?
|
| Muscle Weakness | 1 | 2014 | 33 | 0.440 |
Why?
|
| Clinical Decision-Making | 4 | 2021 | 166 | 0.440 |
Why?
|
| Anemia, Sickle Cell | 2 | 2025 | 64 | 0.440 |
Why?
|
| Propensity Score | 4 | 2026 | 162 | 0.430 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 937 | 0.430 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 435 | 0.430 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 732 | 0.430 |
Why?
|
| Renal Insufficiency | 2 | 2013 | 65 | 0.420 |
Why?
|
| Hemorrhage | 3 | 2023 | 267 | 0.420 |
Why?
|
| Interleukin-6 | 1 | 2015 | 320 | 0.420 |
Why?
|
| Kidney Tubules | 1 | 2013 | 21 | 0.420 |
Why?
|
| Disease Management | 1 | 2015 | 233 | 0.420 |
Why?
|
| Practice Guidelines as Topic | 7 | 2025 | 725 | 0.410 |
Why?
|
| Oxygen | 4 | 2023 | 317 | 0.410 |
Why?
|
| Incidental Findings | 3 | 2022 | 45 | 0.410 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 92 | 0.410 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 316 | 0.400 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 99 | 0.400 |
Why?
|
| Physicians | 1 | 2019 | 475 | 0.400 |
Why?
|
| Enteral Nutrition | 3 | 2019 | 54 | 0.380 |
Why?
|
| Cardiac Catheterization | 2 | 2014 | 287 | 0.370 |
Why?
|
| Clarithromycin | 1 | 2011 | 6 | 0.370 |
Why?
|
| Erythromycin | 1 | 2011 | 4 | 0.370 |
Why?
|
| Pentoxifylline | 1 | 2011 | 8 | 0.370 |
Why?
|
| Fibrinolytic Agents | 3 | 2020 | 170 | 0.370 |
Why?
|
| Disease Progression | 4 | 2017 | 1172 | 0.360 |
Why?
|
| Azithromycin | 1 | 2011 | 32 | 0.360 |
Why?
|
| Macrolides | 1 | 2011 | 38 | 0.360 |
Why?
|
| Electronic Health Records | 4 | 2025 | 361 | 0.360 |
Why?
|
| Respiratory Therapy | 1 | 2011 | 12 | 0.360 |
Why?
|
| Acute Disease | 3 | 2018 | 672 | 0.350 |
Why?
|
| Algorithms | 7 | 2024 | 1005 | 0.350 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2024 | 158 | 0.350 |
Why?
|
| Electrocardiography | 6 | 2021 | 554 | 0.350 |
Why?
|
| Contusions | 1 | 2011 | 11 | 0.350 |
Why?
|
| Bias | 2 | 2022 | 112 | 0.350 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2011 | 33 | 0.340 |
Why?
|
| Glycopeptides | 1 | 2010 | 12 | 0.340 |
Why?
|
| Long-Term Care | 3 | 2019 | 177 | 0.340 |
Why?
|
| Oxazolidinones | 1 | 2010 | 14 | 0.340 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2010 | 11 | 0.340 |
Why?
|
| Acetamides | 1 | 2010 | 13 | 0.340 |
Why?
|
| Ventricular Premature Complexes | 2 | 2021 | 21 | 0.340 |
Why?
|
| Child, Hospitalized | 4 | 2024 | 16 | 0.330 |
Why?
|
| Scleroderma, Systemic | 1 | 2010 | 21 | 0.330 |
Why?
|
| Quality of Life | 1 | 2017 | 1241 | 0.330 |
Why?
|
| Healthcare Disparities | 3 | 2025 | 365 | 0.330 |
Why?
|
| Acid-Base Equilibrium | 1 | 2009 | 7 | 0.320 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 205 | 0.320 |
Why?
|
| Blood Gas Analysis | 1 | 2009 | 34 | 0.320 |
Why?
|
| Qualitative Research | 5 | 2025 | 697 | 0.320 |
Why?
|
| Neoplasms | 4 | 2024 | 1370 | 0.320 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 65 | 0.320 |
Why?
|
| Cardiovascular System | 1 | 2010 | 40 | 0.320 |
Why?
|
| Prospective Studies | 9 | 2022 | 3303 | 0.310 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 2588 | 0.310 |
Why?
|
| Hospitals, Special | 1 | 2009 | 9 | 0.310 |
Why?
|
| Critical Care Outcomes | 2 | 2021 | 2 | 0.310 |
Why?
|
| Evidence-Based Medicine | 3 | 2021 | 462 | 0.310 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2021 | 165 | 0.300 |
Why?
|
| Confidence Intervals | 3 | 2022 | 240 | 0.300 |
Why?
|
| Exercise Test | 1 | 2010 | 252 | 0.290 |
Why?
|
| Digoxin | 2 | 2020 | 22 | 0.290 |
Why?
|
| Amiodarone | 2 | 2020 | 22 | 0.290 |
Why?
|
| APACHE | 3 | 2014 | 43 | 0.290 |
Why?
|
| Asthma | 2 | 2024 | 460 | 0.290 |
Why?
|
| Calcium Channel Blockers | 2 | 2020 | 59 | 0.290 |
Why?
|
| Adolescent | 9 | 2025 | 6255 | 0.280 |
Why?
|
| Wakefulness | 3 | 2025 | 43 | 0.280 |
Why?
|
| Regression Analysis | 2 | 2019 | 499 | 0.280 |
Why?
|
| Child | 11 | 2025 | 4533 | 0.280 |
Why?
|
| Ventilator-Induced Lung Injury | 2 | 2017 | 10 | 0.270 |
Why?
|
| Sex Factors | 5 | 2018 | 979 | 0.270 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2020 | 151 | 0.270 |
Why?
|
| Young Adult | 6 | 2023 | 4708 | 0.270 |
Why?
|
| Linear Models | 2 | 2019 | 409 | 0.270 |
Why?
|
| Multicenter Studies as Topic | 3 | 2025 | 150 | 0.260 |
Why?
|
| Pandemics | 5 | 2023 | 672 | 0.250 |
Why?
|
| Data Collection | 2 | 2020 | 384 | 0.250 |
Why?
|
| Catheter-Related Infections | 2 | 2024 | 44 | 0.250 |
Why?
|
| Milrinone | 1 | 2026 | 1 | 0.250 |
Why?
|
| Dobutamine | 1 | 2026 | 11 | 0.250 |
Why?
|
| Patient Transfer | 2 | 2017 | 93 | 0.250 |
Why?
|
| Machine Learning | 4 | 2024 | 179 | 0.240 |
Why?
|
| Phenobarbital | 2 | 2022 | 12 | 0.240 |
Why?
|
| Administration, Oral | 2 | 2024 | 370 | 0.240 |
Why?
|
| Diabetes Mellitus | 2 | 2025 | 541 | 0.240 |
Why?
|
| Cardiotonic Agents | 1 | 2026 | 54 | 0.240 |
Why?
|
| Propofol | 1 | 2025 | 24 | 0.240 |
Why?
|
| Survival Analysis | 4 | 2019 | 585 | 0.230 |
Why?
|
| Statistics, Nonparametric | 4 | 2020 | 215 | 0.230 |
Why?
|
| Multifactorial Inheritance | 1 | 2025 | 26 | 0.230 |
Why?
|
| Etomidate | 1 | 2024 | 8 | 0.220 |
Why?
|
| Shock, Cardiogenic | 1 | 2026 | 104 | 0.220 |
Why?
|
| Phenylephrine | 2 | 2022 | 18 | 0.220 |
Why?
|
| Boston | 3 | 2025 | 253 | 0.220 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1258 | 0.220 |
Why?
|
| Veterans | 2 | 2024 | 766 | 0.220 |
Why?
|
| Weight Reduction Programs | 1 | 2025 | 57 | 0.220 |
Why?
|
| Ketamine | 1 | 2024 | 38 | 0.220 |
Why?
|
| Biomedical Research | 3 | 2024 | 268 | 0.220 |
Why?
|
| Sarcoidosis | 1 | 2024 | 33 | 0.220 |
Why?
|
| Atrial Premature Complexes | 2 | 2021 | 13 | 0.220 |
Why?
|
| Blood Proteins | 1 | 2024 | 76 | 0.210 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 64 | 0.210 |
Why?
|
| Virus Diseases | 2 | 2022 | 120 | 0.210 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2024 | 13 | 0.210 |
Why?
|
| Outpatients | 1 | 2025 | 138 | 0.210 |
Why?
|
| Blood Coagulation | 1 | 2024 | 39 | 0.210 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2024 | 35 | 0.210 |
Why?
|
| Self-Management | 1 | 2025 | 63 | 0.210 |
Why?
|
| Hypoxia | 2 | 2021 | 115 | 0.210 |
Why?
|
| Societies, Medical | 3 | 2024 | 379 | 0.210 |
Why?
|
| Potassium | 1 | 2024 | 100 | 0.210 |
Why?
|
| Conscious Sedation | 1 | 2024 | 39 | 0.210 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2021 | 63 | 0.210 |
Why?
|
| Hospitals, Teaching | 2 | 2023 | 107 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 699 | 0.210 |
Why?
|
| Primary Health Care | 3 | 2025 | 695 | 0.200 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 47 | 0.200 |
Why?
|
| Liver Cirrhosis | 1 | 2025 | 173 | 0.200 |
Why?
|
| Methimazole | 1 | 2023 | 8 | 0.200 |
Why?
|
| Thyroid Crisis | 1 | 2023 | 5 | 0.200 |
Why?
|
| Blood Pressure | 2 | 2023 | 512 | 0.200 |
Why?
|
| Coronavirus | 1 | 2023 | 14 | 0.200 |
Why?
|
| Catheterization, Peripheral | 1 | 2023 | 53 | 0.200 |
Why?
|
| Methadone | 1 | 2024 | 134 | 0.200 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 89 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2024 | 151 | 0.190 |
Why?
|
| Causality | 1 | 2022 | 58 | 0.190 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 377 | 0.190 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2024 | 90 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 136 | 0.190 |
Why?
|
| Trust | 1 | 2023 | 75 | 0.190 |
Why?
|
| Token Economy | 1 | 2022 | 7 | 0.190 |
Why?
|
| Health Care Costs | 1 | 2024 | 215 | 0.190 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 237 | 0.190 |
Why?
|
| Bradycardia | 1 | 2022 | 33 | 0.190 |
Why?
|
| Administration, Inhalation | 1 | 2022 | 152 | 0.180 |
Why?
|
| Social Segregation | 1 | 2022 | 10 | 0.180 |
Why?
|
| Research Report | 2 | 2020 | 26 | 0.180 |
Why?
|
| Abortion, Spontaneous | 1 | 2022 | 31 | 0.180 |
Why?
|
| Coinfection | 1 | 2022 | 58 | 0.180 |
Why?
|
| Catheter Ablation | 2 | 2015 | 155 | 0.180 |
Why?
|
| Hypothyroidism | 1 | 2022 | 42 | 0.180 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 15 | 0.180 |
Why?
|
| Extracellular Traps | 1 | 2022 | 43 | 0.180 |
Why?
|
| Ohio | 1 | 2021 | 24 | 0.180 |
Why?
|
| Evidence-Based Practice | 2 | 2024 | 85 | 0.180 |
Why?
|
| Pain Management | 1 | 2024 | 163 | 0.180 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 28 | 0.180 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2022 | 48 | 0.180 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 265 | 0.180 |
Why?
|
| Nitric Oxide | 1 | 2022 | 174 | 0.180 |
Why?
|
| Hospital Costs | 3 | 2020 | 126 | 0.180 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 165 | 0.170 |
Why?
|
| Antioxidants | 1 | 2023 | 252 | 0.170 |
Why?
|
| Skin Diseases | 1 | 2022 | 83 | 0.170 |
Why?
|
| Thoracic Diseases | 1 | 2021 | 15 | 0.170 |
Why?
|
| Vitamin B Complex | 1 | 2020 | 15 | 0.170 |
Why?
|
| Pain | 1 | 2024 | 407 | 0.170 |
Why?
|
| Health Care Rationing | 1 | 2020 | 21 | 0.170 |
Why?
|
| Thiamine | 1 | 2020 | 21 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 332 | 0.170 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 28 | 0.170 |
Why?
|
| Ascorbic Acid | 1 | 2020 | 50 | 0.170 |
Why?
|
| Respiratory Care Units | 1 | 2020 | 1 | 0.170 |
Why?
|
| Frailty | 1 | 2022 | 130 | 0.170 |
Why?
|
| Stress, Psychological | 1 | 2025 | 474 | 0.170 |
Why?
|
| Ecology | 1 | 2020 | 14 | 0.170 |
Why?
|
| Aftercare | 1 | 2020 | 76 | 0.170 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 158 | 0.170 |
Why?
|
| Respiratory Rate | 1 | 2020 | 15 | 0.160 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2020 | 5 | 0.160 |
Why?
|
| Academic Success | 1 | 2020 | 12 | 0.160 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 27 | 0.160 |
Why?
|
| Beds | 1 | 2020 | 10 | 0.160 |
Why?
|
| Respiration Disorders | 1 | 2020 | 25 | 0.160 |
Why?
|
| Microclimate | 1 | 2020 | 1 | 0.160 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 142 | 0.160 |
Why?
|
| Pulmonary Ventilation | 1 | 2020 | 38 | 0.160 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 60 | 0.160 |
Why?
|
| Parents | 1 | 2024 | 393 | 0.160 |
Why?
|
| Societies | 1 | 2020 | 24 | 0.160 |
Why?
|
| Perioperative Period | 1 | 2020 | 21 | 0.160 |
Why?
|
| Obesity | 2 | 2025 | 1234 | 0.160 |
Why?
|
| Respiratory Mechanics | 1 | 2020 | 56 | 0.160 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 141 | 0.160 |
Why?
|
| Diagnosis-Related Groups | 1 | 2020 | 87 | 0.160 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2019 | 30 | 0.160 |
Why?
|
| Cardiovascular Agents | 1 | 2021 | 106 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 1667 | 0.160 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 111 | 0.160 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2020 | 73 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 126 | 0.150 |
Why?
|
| Mass Screening | 1 | 2025 | 691 | 0.150 |
Why?
|
| Mentors | 1 | 2020 | 121 | 0.150 |
Why?
|
| Dementia | 1 | 2022 | 262 | 0.150 |
Why?
|
| England | 1 | 2019 | 30 | 0.150 |
Why?
|
| Palliative Care | 2 | 2021 | 234 | 0.150 |
Why?
|
| Patient Care Planning | 1 | 2019 | 83 | 0.150 |
Why?
|
| Brazil | 1 | 2019 | 100 | 0.150 |
Why?
|
| Program Development | 1 | 2019 | 207 | 0.150 |
Why?
|
| Career Choice | 1 | 2020 | 132 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 148 | 0.150 |
Why?
|
| Radiology | 1 | 2022 | 255 | 0.140 |
Why?
|
| Government Regulation | 1 | 2018 | 41 | 0.140 |
Why?
|
| Intubation, Intratracheal | 3 | 2025 | 203 | 0.140 |
Why?
|
| Blood Glucose | 1 | 2021 | 484 | 0.140 |
Why?
|
| Thromboembolism | 1 | 2018 | 73 | 0.140 |
Why?
|
| Bayes Theorem | 3 | 2024 | 122 | 0.140 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2020 | 127 | 0.140 |
Why?
|
| Prevalence | 3 | 2025 | 1383 | 0.140 |
Why?
|
| Child, Preschool | 4 | 2025 | 1998 | 0.140 |
Why?
|
| Inventories, Hospital | 1 | 2017 | 3 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2019 | 487 | 0.130 |
Why?
|
| Health Promotion | 1 | 2022 | 500 | 0.130 |
Why?
|
| Hospital Charges | 1 | 2017 | 23 | 0.130 |
Why?
|
| United Arab Emirates | 1 | 2017 | 4 | 0.130 |
Why?
|
| Patient Participation | 1 | 2019 | 230 | 0.130 |
Why?
|
| Insulin | 1 | 2021 | 686 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 267 | 0.130 |
Why?
|
| Lactic Acid | 1 | 2017 | 76 | 0.130 |
Why?
|
| Insurance Claim Review | 1 | 2017 | 76 | 0.130 |
Why?
|
| Vasopressins | 1 | 2016 | 15 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 1152 | 0.130 |
Why?
|
| Perception | 1 | 2017 | 176 | 0.130 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 508 | 0.130 |
Why?
|
| Pamphlets | 1 | 2016 | 17 | 0.130 |
Why?
|
| Clostridium Infections | 1 | 2017 | 49 | 0.130 |
Why?
|
| Parenteral Nutrition | 1 | 2016 | 21 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 486 | 0.120 |
Why?
|
| Pilot Projects | 3 | 2019 | 1014 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2016 | 201 | 0.120 |
Why?
|
| North Carolina | 1 | 2016 | 71 | 0.120 |
Why?
|
| Shock | 1 | 2016 | 33 | 0.120 |
Why?
|
| Utah | 1 | 2015 | 7 | 0.120 |
Why?
|
| Internal Medicine | 1 | 2017 | 160 | 0.120 |
Why?
|
| Heart Atria | 3 | 2021 | 137 | 0.120 |
Why?
|
| Risk | 1 | 2016 | 378 | 0.120 |
Why?
|
| Albuterol | 1 | 2015 | 24 | 0.120 |
Why?
|
| Referral and Consultation | 3 | 2025 | 426 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 421 | 0.110 |
Why?
|
| Protein C | 1 | 2014 | 26 | 0.110 |
Why?
|
| ROC Curve | 2 | 2025 | 282 | 0.110 |
Why?
|
| Bronchodilator Agents | 1 | 2015 | 119 | 0.110 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1105 | 0.110 |
Why?
|
| Health Status Indicators | 1 | 2014 | 95 | 0.110 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2014 | 30 | 0.110 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 784 | 0.100 |
Why?
|
| Biopsy | 1 | 2015 | 446 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 1648 | 0.100 |
Why?
|
| Infection Control | 1 | 2014 | 106 | 0.100 |
Why?
|
| Utilization Review | 1 | 2013 | 32 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 313 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2025 | 523 | 0.100 |
Why?
|
| Steroids | 2 | 2023 | 55 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 477 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2014 | 308 | 0.090 |
Why?
|
| Staphylococcus aureus | 2 | 2014 | 176 | 0.090 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2011 | 5 | 0.090 |
Why?
|
| Poisson Distribution | 1 | 2011 | 53 | 0.090 |
Why?
|
| Trauma Severity Indices | 1 | 2011 | 34 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 299 | 0.090 |
Why?
|
| Linezolid | 1 | 2010 | 6 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 375 | 0.090 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 156 | 0.080 |
Why?
|
| Hospitals, University | 1 | 2010 | 55 | 0.080 |
Why?
|
| Ontario | 2 | 2020 | 45 | 0.080 |
Why?
|
| Recurrence | 3 | 2020 | 642 | 0.080 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 79 | 0.080 |
Why?
|
| Pneumonectomy | 1 | 2011 | 114 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 190 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 455 | 0.080 |
Why?
|
| Stroke Volume | 2 | 2021 | 329 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2017 | 809 | 0.080 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 268 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 169 | 0.080 |
Why?
|
| Gram-Negative Bacteria | 1 | 2009 | 57 | 0.070 |
Why?
|
| Infant | 2 | 2025 | 1654 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 150 | 0.070 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2009 | 57 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1096 | 0.070 |
Why?
|
| Health Expenditures | 2 | 2022 | 122 | 0.070 |
Why?
|
| Drug Utilization | 2 | 2020 | 209 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 422 | 0.070 |
Why?
|
| Paracentesis | 1 | 2006 | 12 | 0.060 |
Why?
|
| Pleural Effusion | 1 | 2006 | 40 | 0.060 |
Why?
|
| Pressure | 1 | 2006 | 79 | 0.060 |
Why?
|
| Pneumothorax | 1 | 2006 | 50 | 0.060 |
Why?
|
| Patient Selection | 2 | 2020 | 490 | 0.060 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2025 | 26 | 0.060 |
Why?
|
| Computers, Handheld | 1 | 2025 | 38 | 0.060 |
Why?
|
| Spirometry | 1 | 2025 | 112 | 0.060 |
Why?
|
| Forced Expiratory Volume | 1 | 2025 | 209 | 0.050 |
Why?
|
| SEER Program | 1 | 2024 | 74 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2024 | 82 | 0.050 |
Why?
|
| New England | 1 | 2025 | 275 | 0.050 |
Why?
|
| Cough | 1 | 2006 | 183 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 682 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2024 | 101 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2024 | 26 | 0.050 |
Why?
|
| Pyridones | 1 | 2024 | 41 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 2699 | 0.050 |
Why?
|
| Propylthiouracil | 1 | 2023 | 8 | 0.050 |
Why?
|
| Antithyroid Agents | 1 | 2023 | 19 | 0.050 |
Why?
|
| Alberta | 1 | 2022 | 5 | 0.050 |
Why?
|
| Minority Groups | 1 | 2024 | 138 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2025 | 311 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2022 | 22 | 0.050 |
Why?
|
| Narcotic Antagonists | 1 | 2024 | 136 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2022 | 34 | 0.050 |
Why?
|
| Cannula | 1 | 2022 | 24 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 65 | 0.050 |
Why?
|
| International Agencies | 1 | 2021 | 7 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2022 | 58 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2022 | 194 | 0.050 |
Why?
|
| Death | 1 | 2021 | 31 | 0.050 |
Why?
|
| Health Facilities | 1 | 2022 | 43 | 0.050 |
Why?
|
| Warfarin | 1 | 2022 | 112 | 0.050 |
Why?
|
| Wavelet Analysis | 1 | 2021 | 5 | 0.050 |
Why?
|
| Creatinine | 1 | 2022 | 135 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 143 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 37 | 0.040 |
Why?
|
| Support Vector Machine | 1 | 2021 | 23 | 0.040 |
Why?
|
| Opiate Substitution Treatment | 1 | 2024 | 206 | 0.040 |
Why?
|
| Age Distribution | 1 | 2022 | 259 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2024 | 341 | 0.040 |
Why?
|
| Smartphone | 1 | 2022 | 69 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2022 | 85 | 0.040 |
Why?
|
| Aspirin | 1 | 2022 | 172 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 169 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 24 | 0.040 |
Why?
|
| Radiography | 1 | 2022 | 551 | 0.040 |
Why?
|
| Global Health | 1 | 2022 | 183 | 0.040 |
Why?
|
| New York | 1 | 2020 | 145 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2021 | 98 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2022 | 219 | 0.040 |
Why?
|
| Role | 1 | 2020 | 14 | 0.040 |
Why?
|
| Physical Examination | 1 | 2020 | 111 | 0.040 |
Why?
|
| Vitamins | 1 | 2020 | 80 | 0.040 |
Why?
|
| Electric Impedance | 1 | 2020 | 36 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2021 | 125 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 268 | 0.040 |
Why?
|
| Professional Competence | 1 | 2020 | 93 | 0.040 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 125 | 0.040 |
Why?
|
| Neutrophils | 1 | 2022 | 376 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 168 | 0.040 |
Why?
|
| Reference Standards | 1 | 2018 | 73 | 0.040 |
Why?
|
| New York City | 1 | 2018 | 90 | 0.040 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2018 | 19 | 0.040 |
Why?
|
| Financing, Organized | 1 | 2018 | 16 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 254 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 863 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 331 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2020 | 198 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2018 | 79 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2022 | 869 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 133 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 764 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2020 | 479 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 117 | 0.030 |
Why?
|
| Chest Wall Oscillation | 1 | 2017 | 2 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2018 | 101 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 456 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 2018 | 149 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2015 | 1314 | 0.030 |
Why?
|
| Microbiota | 1 | 2018 | 129 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 262 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 576 | 0.030 |
Why?
|
| Thyrotoxicosis | 1 | 2015 | 7 | 0.030 |
Why?
|
| Alcoholic Intoxication | 1 | 2015 | 27 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 1181 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2334 | 0.030 |
Why?
|
| Enterococcus | 1 | 2014 | 10 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 443 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2013 | 79 | 0.020 |
Why?
|
| Cardiology | 1 | 2015 | 168 | 0.020 |
Why?
|
| Washington | 1 | 2012 | 26 | 0.020 |
Why?
|
| Thyroid Function Tests | 1 | 2012 | 14 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3397 | 0.020 |
Why?
|
| Pericardial Effusion | 1 | 2012 | 21 | 0.020 |
Why?
|
| Atrial Flutter | 1 | 2012 | 23 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2018 | 797 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 294 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 20675 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 60 | 0.020 |
Why?
|
| Patient Admission | 1 | 2012 | 198 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 89 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 244 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 88 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 485 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 280 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 418 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 981 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 517 | 0.020 |
Why?
|
| Manometry | 1 | 2006 | 25 | 0.020 |
Why?
|
| Chest Pain | 1 | 2006 | 84 | 0.010 |
Why?
|